UNSPSC 51172837: Sodium biphosphate/sodium fluoride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.

UNSPSC 51172837 Sodium biphosphate/sodium fluoride is a Commodity code under which state and local governments procure pharmaceutical and over-the-counter products through cooperative purchasing vehicles and multi-source supplier agreements. The recent activity shows that this code is used to tag broader pharmaceutical procurement efforts rather than single-ingredient products — state and local buyers are establishing master supplier contracts for generic pharmaceuticals and OTC products across multiple therapeutic categories, with manufacturers required to supply identified products via authorized wholesaler channels and to maintain cGMP and Drug Supply Chain Security Act compliance.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The solicitation closed March 26, 2026, and required vendors to submit detailed product information including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing location through designated Excel spreadsheet format via the ePro procurement system. Evaluation weighted price competitiveness at 75 percent, with the remaining 25 percent divided among fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors' products will be available through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026, for a two-year term with optional extensions.